Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unnamed big pharma evaluates Merrion's oral delivery platform for three compounds

This article was originally published in Scrip

Executive Summary

Merrion Pharmaceuticals, a publicly listed Irish drug development company, has announced that it has signed an oral drug delivery feasibility and option agreement with an unnamed top ten pharmaceutical company. Under the terms of the agreement, the partners will evaluate Merrion’s GIPET technology for boosting the bioavailablity of three compounds belonging to the pharma firm.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts